Amryt Pharma PLC (LON:AMYT) has announced the appointment of Kieran Rooney as its Vice President of Strategic Alliances and Licensing.
In a statement, the AIM-listed biopharmaceutical company focused on treatments for rare and orphan diseases, said Dr Rooney has over 25 years of experience in the biopharmaceutical industry, with significant expertise in business development and commercial strategy.
WATCH: Amryt Pharma making major advances after successful Lojuxta trial
Joe Wiley, CEO of Amryt said: "I am pleased to welcome Kieran to our senior management team.
“In this new leadership role, Kieran will be responsible for assessing new acquisition and in-licencing opportunities as we continue to execute our strategy to acquire, develop and commercialise products to enhance the lives of patients with rare and orphan diseases.”
Wiley added: “We are excited to continue our buildout of critical leadership roles across the organization as we progress our broadening commercial stage pipeline to the benefit of patients with rare and orphan diseases."
Before joining Amryt, Rooney founded Halo BioConsulting, a global healthcare advisory services firm focusing on business alliances and management consulting.
Prior to that, he worked as a consultant for the UK Government and held business development roles at companies including Smith & Nephew, F2G Limited, Pharsight Corporation, and MDS Pharma Services.